Attendee search 

NeuroTronik Limited is a development-stage, venture-backed medical device company pursuing a unique neuromodulation approach to improve cardac output for patients who come to the hospital with Acute Heart Failure Syndrome. With a seasoned team of engineers, advisors, and investors, NeuroTronik is on-track in project milestone achievement. Though a moderately-sized project, the market potential is exceptional.

NeuroTronik is planning a $20 million Series B preferred stock financing in late 2015. Those proceeds are designed to take the therapy through and into commercial sales in Europe.

Our named investors are Hatteras Venture Partners, Synergy Life Science Partners, Mountain Group Capital, and Lord Baltimore Capital.

The CEO is Fred McCoy. The CTO is Steve Masson.

The Advanced Medical Technology Association (AdvaMed), is a trade association that leads the effort to advance medical technology in order to achieve healthier lives and healthier economies around the world. AdvaMed represents 80 percent of medical technology firms in the United States and acts as the common voice for companies producing medical devices, diagnostic products and health information systems. AdvaMed members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 40 percent purchased annually around the world. AdvaMed's member companies range from the largest to the smallest medical technology innovators and companies.

AdvaMed 2015 - October 5-7, San Diego - is the leading MedTech Conference in North America, bringing more than 1,000 companies together in a uniquely multifaceted environment for business development, capital formation, innovative technology showcasing, world-class educational opportunities and networking. An event rich in international flavor and featuring a deep, diverse attendee list that includes influential policy-makers, business executives and media, AdvaMed 2015 seeks to advance industry discussion from key perspectives through detailed panel sessions, executive forums and more. It is a “must-attend” event for any MedTech company.

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Life Science Nation (LSN) is the premier sourcing platform for market intelligence and prospect pipeline development in the life science arena. LSN enables life science professionals to generate a list of qualified global targets that are a fit for their company’s products, services, and fundraising efforts. The ability to generate these Global Target Lists (GTLs) makes life science professionals more effective and efficient. 

Johnson & Johnson (J&J) was founded in 1886 and is based in New Brunswick, NJ, with an Innovation Center in Cambridge, MA. The firm invests in a variety of fields within the life science sector, including medical devices. J&J’s medical device investments are highly varied in both size and structure; the structure may involve milestone payments, or may be an equity investment. J&J is interested in early stage medical device companies located globally.

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.

JBI is a Midwest-based biotechnology company driven to develop a new class of therapies to treat patients with Alzheimer’s disease and other neurodegenerative diseases. 

JBI’s unique approach is able to lower the production of Amyloid Beta (Aβ), phosphorylated Tau (pTau) and toxic intracellular Aβ aggregates.  Our passion is to develop a therapy to restore the patient’s lifespan and improve patient quality of life.

JBI is focused on further developing its lead compound, JBI-009, based on the strength of compelling preclinical safety and efficacy results to date.

JBI’s approach represents a new wave in thinking about the treatment of AD.  Currently available drugs treat disease symptoms, rather than its suspected cause, and do so with limited success.  Most drugs in late-stage clinical development are attempting to address a likely cause of the disease, the accumulation of Aβ, by potently inhibiting the enzyme responsible for Aβ production.  As this enzyme has other important biological functions, this approach has seen early failures because of unacceptable side effects.  JBI's approach is unique in that it modulates the production of this enzyme rather than inhibits its activity.  JBI’s approach is expected to restore enzyme activity and Aβ production to normal levels with a favorable safety advantage.

JBI’s technology is also unique in that it targets cellular machinery within the Endoplasmic Reticulum (ER).  Most drug developers have focused on modifying activity that occurs either on the cell membrane or within the cell nucleus or cytosol.  JBI is one of the first, if not the first, to successfully target activity within the ER.  The discoveries employed by JBI have produced a lead compound that affects the enzyme responsible for controlling the rate-limiting step in Aβ production, penetrates the blood brain barrier, and shows no toxicity in IND feasibility safety studies.  In addition, work has begun on next generation compounds.  This ER-focused approach provides platform potential for future therapies to treat additional significant unmet medical needs.